PatientsVille.com LogoPatientsVille.com

Sinusitis | Pulmozyme in Cystic Fibrosis With Sinusitis

Sinusitis research study

What is the primary objective of this study?

The hypothesis is that the intranasal use of Pulmozyme will decrease the severity of sinusitis in Cystic Fibrosis and lead to an improved quality of life.

Who is eligible to participate?

Inclusion Criteria: 1. Patients with CF, age >15yo 2. Chronic sinusitis with symptoms 3. VAS score of at least 60 (0 to 100) reflecting symptoms associated with rhinosinusitis 4. CT scan demonstrating non-complicated sinusitis (defined as rhinosinusitis without orbit perforation, osteomyelitis, peri-sinus cellulitis, or meningitis) Exclusion Criteria: 1. No evidence of sinusitis 2. VAS score for rhinosinusitis less than 60 on a scale of 0 to 100 3. Complicated sinusitis (defined as orbit perforation, osteomyelitis, peri-sinus cellulitis, meningitis complicating sinusitis) 4. Prior adverse events or allergy to DNASE 5. Unwilling to sign an approved IRB consent 6. Immediate indication for sinus surgery 7. Inability to adhere to therapy and understand and to complete questionnaires. 8. Being pregnant will exclude a subject from participating and the subjects will be requested to take birth control methods if actively engaging in sex. Further more, subjects will be requested to inform the investigators if they become pregnant. Pregnancy test will be performed at screening. 9. Active nursing of an infant will be an exclusion.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Sinusitis

Cystic Fibrosis

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Pulmozyme single use ampuleā€¢ Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.

Drug:placeboidentical placebo

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

PULMOZYMEactive drug

placebocross over to placebo

Study Status

Withdrawn

Start Date: July 2013

Completed Date: June 2015

Phase: Phase 3

Type: Interventional

Design:

Primary Outcome: 1. To assess changes in quality of life of patients with Cystic Fibrosis while on DNASE as compared to placebo.

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Timothy Craig, DO

Lead Sponsor: Milton S. Hershey Medical Center

Collaborator: Genentech, Inc.

More information:https://clinicaltrials.gov/show/NCT01155752

Discuss Sinusitis